2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2017
Stress, cortisol, and other appetite‐related hormones: Prospective prediction of 6‐month changes in food cravings and weight
Chao AM, Jastreboff AM, White MA, Grilo CM, Sinha R. Stress, cortisol, and other appetite‐related hormones: Prospective prediction of 6‐month changes in food cravings and weight. Obesity 2017, 25: 713-720. PMID: 28349668, PMCID: PMC5373497, DOI: 10.1002/oby.21790.Peer-Reviewed Original ResearchConceptsFuture weight gainAppetite-related hormonesFood cravingsChronic stressWeight gainProspective community cohortFood Craving InventoryTotal ghrelinCommunity cohortBlood drawMorning cortisolClinical covariatesHormone levelsBody weightCortisol responseHigher food cravingsHigher cortisolCortisolCumulative Adversity InterviewCravingLinear mixed modelsBaselineGhrelinHormoneMonths